GMP Supplier Qualification Training: Keep Unsafe Materials Out of Your Medicines

Opens with a drum of excipient arriving with a perfect certificate of analysis, and the question of how you know what is inside. Covers three cases: cough syrups for children contaminated with diethylene glycol and ethylene glycol in 2022 and 2023, with WHO reporting more than 300 deaths in three countries; FDA's May 2025 letter to Laboratoire Druide in Canada; and its August 2026 letter to Safrel Pharmaceuticals in New Jersey. Shows that responsibility for materials stays with the medicine maker. Introduces JKL Pharma's sites in Mumbai and Singapore, clears four myths, from trusting the certificate to 'once approved, always approved', and outlines the ten modules, the final exam and the certificate. It ends with a recap and three practice questions.

What you will be able to do

• Explain why the medicine maker stays responsible for its materials
• Recognise the supplier failures behind recent FDA and WHO cases
• Describe how the course and final exam work

Why it matters

Seeing how trusted paperwork let toxic excipients through shows why your own supplier checks matter.

Practice: Practice: Welcome: why supplier qualification matters · 3 questions

Returns to the Druide case, where FDA found no identity test on each component and reliance on suppliers' certificates without checking their reliability, including glycerin not tested for diethylene and ethylene glycol. Covers US rules requiring an identity test on each component, with certificates allowed only once their reliability is established. Explains EU GMP's documented, risk-based supplier control, supply chain traceability for active substances with audits, and formal risk assessment for excipients under the Commission's guidelines of March 2015. Covers ICH Q10's four processes: assess, define, monitor and verify. Shows how JKL Pharma's corporate quality team maps each rule to a procedure, and why a GMP certificate never qualifies a supplier by itself. It ends with a recap and three practice questions.

What you will be able to do

• Explain US identity testing and certificate reliability rules
• Describe EU expectations for active substance and excipient suppliers
• Apply the four ICH Q10 processes to a supplier programme

Why it matters

Knowing exactly what the rules ask lets you show inspectors your own evidence rather than a supplier's certificate.

Practice: Practice: What the rules require · 3 questions

Returns to the contaminated syrups, where an inexpensive propylene glycol excipient, not the active ingredient, caused the harm. Covers building a full map of what a site buys: actives, excipients, processing aids such as solvents and filter aids, and packaging, with each manufacturer, each supplier or distributor in between and each site that uses it. Explains rating each material on the risks from its source and supply chain and from its use: the dosage form, the route and what the material does in the formulation. Shows part of JKL Pharma's risk register and rating method, including metformin from its sister company JKL Fine Chemicals, checking materials against FDA's high-risk list, and reviewing ratings every year and after every defect or alert. It ends with a recap and three practice questions.

What you will be able to do

• Map every material with its manufacturer and supply chain
• Rate a material's risk from its source, supply chain and use
• Let the risk rating decide the supplier controls

Why it matters

Rating risk properly puts your effort on the materials that could hurt patients, including ordinary excipients.

Practice: Practice: Mapping and rating risk · 3 questions

Returns to Safrel Pharmaceuticals, where FDA found no quality oversight of suppliers or contract manufacturers and no certificates of analysis kept. Covers collecting the evidence: who makes the material, what certificates and data the supplier holds, and its regulatory history. Works through JKL Pharma's assessment of a new povidone binder supplier, an excipient maker in Frankfurt with a named site and direct supply, its questionnaire, GMP certificate and certificate of analysis. Explains comparing the GMP the material needs with what the supplier can show, documenting gaps, rating the supplier, choosing a strategy, approving with the evidence on file, and enforcing the approved supplier list, linked at JKL to the warehouse system, with clear grounds for disqualification. It ends with a recap and three practice questions.

What you will be able to do

• Collect the evidence needed to assess a new supplier
• Document gaps between required and demonstrated GMP
• Approve a supplier and enforce the approved list at delivery

Why it matters

Assessing before the first order means an urgent purchase never brings in a supplier nobody has checked.

Practice: Practice: Assessing a new supplier · 3 questions

Opens with an excipient maker whose questionnaire said dedicated equipment, until the auditor found a final dryer shared with a pesticide intermediate and incomplete cleaning records. Covers when audits are needed: in the EU, makers and distributors of active substances are audited, and for other materials the risk decides. Explains who can audit, giving an audit the duration and scope for a full and clear view, and why a generic checklist ticked in a meeting room by lunchtime is not enough. Shows a summary of JKL Pharma's audit of its sister company JKL Fine Chemicals, which stayed approved with a corrective action due in sixty days and the next five lots fully tested. Covers reports that show what was seen, follow-up with evidence and a risk-based schedule. It ends with a recap and three practice questions.

What you will be able to do

• Decide when a supplier audit is needed by material and risk
• Plan an audit scope that covers cross-contamination
• Follow up audit findings with evidence before the next audit

Why it matters

An audit that looks at the process, not the paperwork, finds risks no questionnaire will ever report.

Practice: Practice: Supplier audits · 3 questions

Starts with a tablet maker whose lubricant supplier moved to a new plant under the same grade name, until dissolution results drifted from a change in particle size that no agreement required it to report. Covers the specification, which sets your requirements for each material and is agreed with the supplier, and the quality agreement, which sets who does each GMP activity, using a chart, matrix or narrative as FDA allows. Shows the outline of JKL Pharma's quality agreement with its new povidone supplier: approval before changes to site, process or raw materials, and deviations and recalls reported within two working days. Explains duties on both sides, no subcontracting without approval, records you can see, and checking whether change notices actually arrived. It ends with a recap and three practice questions.

What you will be able to do

• Write a material specification agreed with the supplier
• Set out GMP responsibilities in a quality agreement
• List the changes that need notice or approval in an agreement

Why it matters

Agreeing requirements and change notice in writing catches a supplier's change before it reaches your product.

Practice: Practice: Specifications and quality agreements · 3 questions

Opens with FDA's June 2025 warning letter to Dynamic Blending Specialists, a Utah over-the-counter drug maker that did not test each component lot for identity, including glycerin, and relied on unverified certificates. Covers identity testing by the user on every batch, normally on every container, a test that is never handed over. Explains when a supplier's certificate can replace other tests: only once its reliability is shown and checked again at intervals by full analysis. Shows part of JKL Pharma's testing plan at receipt built from each material's risk rating, packaging checks, and a Boston tablet maker that suspends a supplier's certificates after a discrepancy. Covers testing high-risk glycol components in every container of every lot. It ends with a recap and three practice questions.

What you will be able to do

• Apply identity testing to every batch and container
• Establish and recheck the reliability of a supplier's certificates
• Test high-risk glycol components in every container of every lot

Why it matters

Your own identity test is the check that stops a wrong or contaminated material being used on trust.

Practice: Practice: Certificates and testing · 3 questions

Starts with an excipient supplier approved after a good audit, whose late certificates and damaged bags were each handled alone until two lots failed in the fourth year. Covers monitoring every supplier after approval: defects, trends, certification, changes and the source of each delivery, with JKL's warehouse system blocking unapproved makers or sites. Explains the yearly review of every supplier with real data, triggers such as major changes or regulatory action, and keeping, adding controls or disqualifying, as FDA asked of Safrel. Shows four results from JKL Pharma's yearly supplier review, including a foil printer's text error found by JKL's own check, and rubber stoppers at its Singapore site, with the question: would we approve it today? It ends with a recap and three practice questions.

What you will be able to do

• Monitor supplier performance and spot trends across deliveries
• Run a yearly supplier review with real data
• Decide whether to keep, add controls to or disqualify a supplier

Why it matters

Reviewing suppliers every year joins up small warning signs before they become rejected lots or recalls.

Practice: Practice: Monitoring and requalification · 3 questions

Returns to FDA's 2023 guidance on glycol contamination, where certificates were often copies on a distributor's letterhead, the glycerin's origin was not apparent and the chain of custody unknown, a pattern the 2022 outbreak repeated. Covers knowing the original manufacturer behind every distributor, trader or broker, and buying direct where possible. Explains accepting only certificates that name the original maker and batch, with the original attached, and treating a new source, maker or maker's site as a change, assessed and tested before use. Shows how JKL Pharma controls its polyethylene glycol 400 bought through a distributor, and testing broker materials in every container until the source is known and assessed. It ends with a recap and three practice questions.

What you will be able to do

• Identify the original manufacturer behind a distributor or broker
• Accept only certificates that name the original maker and batch
• Treat a new source or maker's site as a change before use

Why it matters

Qualifying the whole chain, not the invoice, closes the gap through which contaminated glycols have reached medicines.

Practice: Practice: Changes and brokers · 3 questions

Opens with the question of whether you could show an inspector the whole story of one material tomorrow. Puts the modules side by side as one life cycle: rate risk, assess the supplier, agree requirements in writing, verify every delivery and monitor and review. Follows the polyethylene glycol 400 in JKL Pharma's tablet coating through the whole programme, and shows how JKL shares the work. Looks back at the syrups and the Druide, Dynamic Blending and Safrel letters, including FDA's request for glycol results within thirty days from retained samples. Gives a five-step road map starting with the riskiest materials, the value of linking the approved list to the warehouse system, and the final exam.

What you will be able to do

• Apply the rate, assess, agree, verify and monitor cycle
• Build one supplier file that tells a material's whole story
• Plan a road map that starts with your riskiest materials

Why it matters

Seeing the whole programme on one material shows where your own supplier files would leave gaps.

Practice: Practice: Putting it together · 3 questions